KT185 is the first orally -active ABHD6-selective inhibitor. It exhibits excellent selectivity against other brain and liver serine hydrolases in vivo. References: Hsu KL, Tsuboi K, Chang JW, Whitby LR, Speers AE, Pugh H, Cravatt BF. Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6). J Med Chem. 2013 Nov 14;56(21):8270-9. doi: 10.1021/jm400899c. Epub 2013 Oct 23. PubMed PMID: 24152295; PubMed Central PMCID: PMC3987869.

纯度：≥98%

CAS：1472640-86-0